Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, Mahlangu J, Young G, Kruse-Jarres R, Mancuso ME, Niggli M, Howard M, Bienz NS, Shima M, Jiménez-Yuste V, Schmitt C, Asikanius E, Levy GG, Pipe SW, Oldenburg J.
Callaghan MU, et al. Among authors: pipe sw.
Blood. 2021 Apr 22;137(16):2231-2242. doi: 10.1182/blood.2020009217.
Blood. 2021.
PMID: 33512413
Free PMC article.
Clinical Trial.